# Management of endometrial hyperplasia

A clinical guideline recommended for use

<table>
<thead>
<tr>
<th>For Use in:</th>
<th>Gynaecology Services</th>
</tr>
</thead>
<tbody>
<tr>
<td>By:</td>
<td>Gynaecologists, nurses</td>
</tr>
<tr>
<td>For:</td>
<td>Management of endometrial hyperplasia</td>
</tr>
<tr>
<td>Division responsible for document:</td>
<td>Women and Children's Division</td>
</tr>
<tr>
<td>Key words:</td>
<td>Endometrial hyperplasia</td>
</tr>
<tr>
<td>Name of document author:</td>
<td>Saadia Naeem, Tim Duncan</td>
</tr>
<tr>
<td>Job title of document author:</td>
<td>Gynaecologists</td>
</tr>
<tr>
<td>Name of document author's Line Manager:</td>
<td>David Booth</td>
</tr>
<tr>
<td>Job title of author's Line Manager:</td>
<td>Chief of Division</td>
</tr>
<tr>
<td>Assessed and approved by the:</td>
<td>(Gynaecology Guidelines Committee)</td>
</tr>
<tr>
<td>Date of approval:</td>
<td>02/09/2016</td>
</tr>
<tr>
<td>Ratified by or reported as approved to (if applicable):</td>
<td>Clinical Standards Group and Effectiveness Sub-Board</td>
</tr>
<tr>
<td>To be reviewed before:</td>
<td>This document remains current after this date but will be under review</td>
</tr>
<tr>
<td></td>
<td>30/09/2019</td>
</tr>
<tr>
<td>To be reviewed by:</td>
<td>Saadia Naeem, Tim Duncan</td>
</tr>
<tr>
<td>Reference and / or Trust Docs ID No:</td>
<td>782</td>
</tr>
<tr>
<td>Version No:</td>
<td>V2 G</td>
</tr>
<tr>
<td>Description of changes:</td>
<td>Updated</td>
</tr>
<tr>
<td>Compliance links:</td>
<td>(is there any NICE related to guidance)</td>
</tr>
<tr>
<td></td>
<td>No NICE</td>
</tr>
<tr>
<td>If Yes - does the strategy/policy deviate from the recommendations of NICE?</td>
<td>N/A</td>
</tr>
<tr>
<td>If so why?:</td>
<td></td>
</tr>
</tbody>
</table>
Management of endometrial hyperplasia

Endometrial hyperplasia (EH) is usually detected following investigation for abnormal uterine bleeding. This can occur in pre and postmenopausal women and management must take into account fertility wishes, medical co-morbidities and risk of cancer progression.

Classification of EH has varied over the years. The World Health Organization (WHO) 2014 classification is recommended. This separates EH into two groups based upon the presence of cytological atypia:

<table>
<thead>
<tr>
<th>Type</th>
<th>Risk of progression</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperplasia without atypia</td>
<td>&lt;5% over 20 years</td>
</tr>
<tr>
<td>Atypical hyperplasia</td>
<td>30%</td>
</tr>
</tbody>
</table>

Associated factors which increased incidence and risk of progression of EH include:

- Unopposed oestrogen therapy
- Obesity (BMI>35)
- Nulliparity
- Diabetes
- Tamoxifen
- PCOS (anovulation)
- Oestrogen secreting tumours (e.g. ovarian granulosa cell tumour)

Symptoms:

- PMB
- IMB
- Menorrhagia
- Irregular cycle

EH can be reliably diagnosed by Pipelle biopsy or hysteroscopic biopsy, however, focal abnormalities within polyps can be missed with Pipelle endometrial sampling.

Hysteroscopy should be undertaken where EH has been diagnosed within a polyp by Pipelle sampling or if there is suspicion of a polyp on ultrasound assessment. Polyps should be removed in their entirety to ensure focal lesions such as areas of carcinoma are identified.

For investigation of PMB see guideline G39.

Reversible risk factors such as obesity and the use of hormone replacement therapy (HRT) should be identified and addressed if possible. Where relevant, weight loss is advised, although the evidence of enhanced regression rates are lacking. Women on HRT should have the indication and preparation reviewed as this may be an opportunity to influence the likelihood of spontaneous regression.

Management of EH without atypia
Management of endometrial hyperplasia

Conservative management

EH without atypia progresses to endometrial cancer in less than 5% of cases over 20 years. The majority will regress spontaneously during the follow-up.\textsuperscript{1,2}

Observation alone, with follow-up endometrial biopsies (6 monthly) to ensure disease regression, can be considered especially when identifiable risk factors can be reversed.

Women should be informed that the treatment with progestogens has a higher disease regression rate compared with observation alone.\textsuperscript{11}

Progestogen treatment is indicated in women who fail to regress following observation alone for 12 months.

Conservative management in symptomatic women with abnormal bleeding is rarely advised.

Medical management

Both continuous oral and local intrauterine [Levonorgestrel-releasing intrauterine system (LNG-IUS)] progestogen is effective in achieving regression.

The LNG-IUS should be the first-line medical treatment because compared to oral progestogens it has a higher disease regression rate and more favourable bleeding profile and fewer adverse effects.\textsuperscript{12}

Continuous progestogens (medroxyprogesterone 10-20 mg/day or norethisterone 10-15 mg/day) should be used for women who decline the LNG-IUS.

Cyclical progestogens should not be used because they are less effective

Treatment with oral progestogens or the LNG-IUS should be for a minimum of 6 months in order to induce histological regression.\textsuperscript{13}

If adverse effects are tolerable and fertility is not desired, women should be encouraged to retain the LNG-IUS for up to 5 years as this reduces the risk of relapse.

After commencement of treatment an outpatient endometrial biopsy is recommended at 6-months. Once reversal has been achieved at least two consecutive negative biopsies, taken 6 monthly, should be obtained prior to discharge.\textsuperscript{14-15}

Due to the high relapse rates in women with a BMI>35 longer term follow-up should be considered with 6 monthly biopsies for 2 years. Following this the decision for ongoing follow up will be at the discretion of the responsible consultant.\textsuperscript{14-15}
Management of endometrial hyperplasia

Women should be asked to seek a further referral if abnormal bleeding recurs after completion of treatment because this may indicate disease relapse.

**Surgical Management**

Hysterectomy should not be considered as a first line treatment for hyperplasia without atypia.

Indications for hysterectomy:
- Progression to atypical hyperplasia
- No histological regression after 12 months of treatment
- Relapse
- Persistence of bleeding in spite of reversal
- Women who decline endometrial surveillance and/or medical treatment

Whenever possible a laparoscopic hysterectomy or vaginal hysterectomy should be offered.

Post-menopausal women requiring hysterectomy should be offered a bilateral salpingo-oopherectomy.

Due to the potential risk of residual hyperplasia both subtotal hysterectomy and endometrial ablation are contraindicated.

For premenopausal women the decision to remove the ovaries should be individualised; however, bilateral salpingectomy should be considered as this may reduce the risk of a future ovarian malignancy. The evidence regarding the effectiveness of prophylactic salpingectomy and the potential effects on ovarian function are yet to be established.

**Management of atypical EH**

Atypical endometrial hyperplasia (AEH) carries a much greater risk of progression to endometrial cancer (up to 50%). Rates of concurrent endometrial cancer may be as high as 40% in patients diagnosed with AEH. Management of patients should be discussed through the Gynaecological Oncology Multidisciplinary Team Meeting.

A pre-treatment pelvic MRI to rule out invasive endometrial cancer or coexisting ovarian cancer is recommended.

**Surgical management of atypical hyperplasia**

Women with atypical hyperplasia should undergo a total hysterectomy because of the risk of progression or underlying cancer. A laparoscopic approach is preferable.

Due to the significant risk of concurrent endometrial cancer, postmenopausal women should also undergo a bilateral salpingo-oopherectomy. In premenopausal women the decision should be individualised, however, it is likely that removal of the ovaries
Management of endometrial hyperplasia

through a second operation would be required if endometrial cancer was identified in the hysterectomy specimen.

Due to the potential risk of residual hyperplasia and/or cancer both subtotal hysterectomy and endometrial ablation are contraindicated.

Non-surgical management of atypical hyperplasia

Prior to considering medical management, where feasible, the patient should undergo hysteroscopy to reduce the risk of missing an occult carcinoma.

Medical management can be considered in the following situations:
- Fertility preservation
- Medically unfit for surgery
- Extreme obesity
- Patient unwilling to undergo surgery

Women should be counselled about the significant risk of underlying or subsequent progression to endometrial cancer which may be at an advanced stage. There is also an associated risk of concurrent ovarian cancer (up to 4%). These factors all have potential prognostic implications (30-50%)\(^8,18\). The need for close monitoring and follow-up needs to be emphasised. The effectiveness of conservative treatment is yet to be established.

First-line treatment with the LNG-IUS is recommended, with oral progestogens as a second best alternative.

Once fertility is no longer required, hysterectomy should be offered in view of the high risk of disease relapse.

Follow up
- 6 monthly until two consecutive negative biopsies
- Evidence for duration of follow up, once regression has occurred, is limited.
- Recurrence risk is highest in the first 2 years, follow up with two annual biopsies is recommended. Following this the decision for ongoing follow up will be at the discretion of the responsible consultant
- Once discharged patients and General Practitioners should be made aware of the symptoms of potential recurrence
- Hysterectomy reconsidered at 12 months if regression has not occurred and also in patients who develop recurrent disease
Management of endometrial hyperplasia

References


Management of endometrial hyperplasia


17. Royal College of Obstetrician and Gynaecologists. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Scientific impact paper No.44.London:RCOG;2014


20. Royal College of Obstetrician and Gynaecologists. The distal fallopian tube as the origin of non-uterine pelvic high-grade serous carcinomas. Scientific impact paper No.44.London:RCOG;2014